French biotech Nosopharm has teamed up with drug discovery expert Evotec to advance lead candidate, NOSO-502, to the clinical stage. The partnership agreement also aims to develop a second-generation Odilorhabdin drug candidate. Financial terms of the deal have not disclosed.
The initial focus will be on chemistry and manufacturing and control (CMC). Work will also include activities related to the clinical trial application (CTA) and filings related to the NOSO-502.
“We are delighted to see that such a renowned industrial biotech partner has decided to support the development of our new class of antibiotics,” said Philippe Villain-Guillot, co-founder and CEO of Nosopharm.
The agreement comes to fruition ahead of the planning of Phase I clinical trials for the treatment of complicated Urinary Tract Infections (cUTI) and complicated intra-abdominal infections (cIAI).
“We are very much looking forward to advancing our first drug candidate into the clinic and to expanding our drug development to a second candidate," Villain-Guillot said.
A new class of odilhorhabdins
NOSO-502 is the first clinical candidate in the novel antibiotic class called Odilhorhabdins (ODLs).
ODLs inhibits the bacterial ribosome with a new mechanism of action and is intended for the treatment of nosocomial infections caused by Enterobacteriaceae, including polymyxin and carbapenem-resistant Enterobacteriaceae (CRE).
NOSO-502 has proven to be effective in vivo in Enterobacteriaceae infection models and demonstrated antibacterial activity in vitro against multi-drug resistant clinical isolates (KPC, NDM and OXA among others).
The second programme will develop a second-generation Odilorhabdin clinical drug candidate for the treatment of hospital-acquired pneumonia and ventilation-associated pne"umonia (HAP/VAP), under the name NOSO-2G. Focus here will be on lead optimisation, profiling for candidate selection and further development.
It’s exciting to see the development of an entirely new antibiotic class, which is crucial in these times of rising antibiotic resistance,” said Dr Cord Dohrmann, Chief Scientific Officer at Evotec.
“We are thrilled to play a key role in this partnership, and we believe that with the unique combination of our infectious disease expertise and drug discovery and early development platforms, the lead candidates will soon enter the clinic and bring hope to physicians and their patients living with nosocomial infections caused by multidrug-resistant bacteria.”
Nosopharm expects CTA-filing to take place in 2021 and to launch first-in-human studies with NOSO-502 in 2021. The clinical candidate selection process for NOSO-2G is expected in 2022.
